Autoimmune Hemolytic Anemia

Introduction

Characterized by premature red blood cell destruction exceeding bone marrow production capacity.
Shortened survival mediated directly by autoantibodies targeting red cell membrane antigens, with or without complement participation.

Categorized primarily by antibody thermal amplitude and optimal binding temperature.
Classified as primary (idiopathic) or secondary to underlying systemic processes.

Classification	Antibody type	Optimal binding temperature	Underlying associations
Warm	Immunoglobulin G	37°C	Idiopathic, systemic lupus erythematosus, immunodeficiencies, autoimmune lymphoproliferative syndrome, lymphoma.
Cold agglutinin disease	Immunoglobulin M	Less than 37°C	Idiopathic, Mycoplasma pneumoniae, Epstein-Barr virus, cytomegalovirus, lymphoproliferative disorders.
Paroxysmal cold hemoglobinuria	Immunoglobulin G (Donath-Landsteiner)	Binds in cold, lyses at 37°C	Nonspecific viral infections, congenital or tertiary syphilis (historically).
Drug-induced	Hapten or immune complex	Variable	Cephalosporins, penicillins, quinine, quinidine, methyldopa, checkpoint inhibitors.

Underpinned by loss of central and peripheral self-tolerance.
Autoreactive B lymphocytes synthesize anti-red cell autoantibodies, supported by T helper lymphocytes.
Molecular mimicry alters red cell membrane antigenicity, inciting inappropriate immune responses.

Immunoglobulin G autoantibodies target "public" antigens, most commonly Rh proteins.
Antibody-coated red cells undergo extravascular hemolysis.
Splenic macrophages identify Fc regions, phagocytosing and destroying affected erythrocytes.
Massive immunoglobulin G quantities occasionally fix complement, triggering intravascular hemolysis.

Immunoglobulin M autoantibodies target I/i system oligosaccharide antigens.
Anti-I specificity frequently associates with Mycoplasma pneumoniae.
Anti-i specificity frequently associates with infectious mononucleosis.
Immunoglobulin M activates complement efficiently; induces intravascular complement-mediated lysis or extravascular hepatic/splenic destruction.

Donath-Landsteiner immunoglobulin G autoantibody exhibits anti-P specificity.
Binds red cells in cold extremities.
Activates complement cascade leading to massive intravascular lysis upon rewarming to 37°C.

Hapten mechanism: drug binds red cell membrane tightly; antibodies target drug molecules leading to splenic destruction (e.g., penicillin).
Ternary complex: drug, membrane antigen, and antibody form complex (e.g., quinine).
True autoantibody induction: drug incites autoantibodies without requiring ongoing drug presence (e.g., methyldopa).

Onset sudden or gradual.
Pallor, fatigue, shortness of breath, dizziness prominent.
Jaundice, scleral icterus, dark urine (hemoglobinuria) present.
Splenomegaly typically noted.
Cardiovascular compromise rare but life-threatening.
Acrocyanosis or extremity agglutination seen in cold antibody disease upon cold exposure.
Concurrent immune thrombocytopenic purpura defines Evans syndrome.

Hemoglobin severely reduced, often dropping below 6 g/dl.
Reticulocytosis prominent, reflecting compensatory marrow hyperplasia.
Reticulocytopenia occasionally observed due to autoantibody targeting marrow precursors, parvovirus infection, or "shocked" marrow.
Leukocytosis frequently present.
Platelet count normal, unless concurrent Evans syndrome exists.

Test modality	Warm antibody	Cold antibody	Paroxysmal cold hemoglobinuria
Direct antiglobulin test	Positive for immunoglobulin G and/or C3	Positive for C3 only	Positive for C3 only
Indirect antiglobulin test	Often positive (free antibody)	Positive	Negative conventionally
Specific assays	Eluate reacts with all test cells (panagglutinin)	Cold agglutinin titer high at <37°C	Donath-Landsteiner test positive

Direct antiglobulin test rarely negative.
Negative direct antiglobulin test requires reference laboratory testing for immunoglobulin A, low-affinity antibodies, or natural killer cell-mediated hemolysis.

Condition	Distinguishing features
Isoimmune hemolytic disease	Neonatal onset, maternal-fetal ABO/Rh incompatibility, positive direct antiglobulin test.
Hereditary spherocytosis	Family history, negative direct antiglobulin test, positive eosin-5-maleimide binding flow cytometry.
Microangiopathic hemolytic anemia	Schistocytes, helmet cells, negative direct antiglobulin test, renal/neurologic involvement.
Glucose-6-phosphate dehydrogenase deficiency	Bite cells, Heinz bodies, oxidant exposure history, negative direct antiglobulin test.
Wilson disease	Negative direct antiglobulin test, liver/central nervous system involvement, high copper.

Blood transfusion: utilize "least incompatible" blood. Administer small volumes (5 ml/kg) slowly (2 ml/kg/h) to prevent cardiopulmonary embarrassment. Coordinate closely with blood bank.
Glucocorticoids: first-line therapy. Administer intravenous methylprednisolone (1-2 mg/kg/day, up to 30 mg/kg daily for 3 days in severe cases) or oral prednisone (2 mg/kg/day). Taper slowly over 4-6 months once hemoglobin stabilizes.
Intravenous immunoglobulin: 0.8-1.0 g/kg/day or up to 5 g/kg total. Response often poor in children; reserved for severe refractory hemolysis.
Rituximab: 375 mg/m2 weekly for 4 weeks. Highly effective for steroid-refractory or steroid-dependent cases.
Plasmapheresis: limited efficacy because immunoglobulin G resides primarily in extravascular spaces.
Immunomodulators: utilized for chronic or refractory management. Options include mycophenolate mofetil (15 mg/kg twice daily), sirolimus (specifically effective in autoimmune lymphoproliferative syndrome and Evans syndrome), cyclosporine, azathioprine, danazol, or bortezomib.
Splenectomy: considered for severe refractory cases unresponsive to medical management. Requires preoperative immunization against encapsulated organisms and lifelong postoperative penicillin prophylaxis. Carries risks of thrombosis and pulmonary hypertension.
Recombinant erythropoietin: indicated strictly for refractory cases manifesting severe reticulocytopenia.

Environmental control: maintain strict warmth; avoid cold exposure.
Transfusion: utilize efficient in-line blood warmer strictly at 37°C. Unmonitored heating is dangerous.
Plasmapheresis: highly efficient due to intravascular immunoglobulin M location.
Rituximab: effective B-lymphocyte depleting agent for chronic or refractory cases.
Glucocorticoids and splenectomy: marginally effective; generally not recommended.

Self-limited course; typically resolves fully in 6-8 weeks.
Environmental control: maintain warm environment.
Transfusion: administer warmed blood for severe symptomatic anemia.
Plasmapheresis or rituximab: reserved exclusively for rare chronic or relapsing cases.

Rare distinct entity presenting aged 6-24 months.
Presents with direct antiglobulin test-positive immune hemolysis, fever, and progressive liver failure.
Requires intensive combined immunosuppression (corticosteroids, cyclophosphamide, rituximab, azathioprine).